NeoGenomics

$54.34
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$1.35 (+2.55%) Today

$0.00 (0.00%) As of 11:01 PM UTC after-hours

Why Robinhood?

You can buy or sell NeoGenomics and other stocks, options, and ETFs commission-free!

About NEO

NeoGenomics, Inc. Common Stock, also called NeoGenomics, is a clinical laboratory company, which specializes in cancer genetics diagnostic testing and pharma services. It operates through the Clinical Services and Pharma Services segments. The Clinical Services segment offers cancer testing services to community-based pathologists, hospitals, academic centers, and oncology groups. The Pharma Services segment focuses on supporting pharmaceutical firms in drug development programs by supporting various clinical trials. The company was founded by Michael T. Dent on October 29, 1998 and is headquartered in Fort Myers, FL. The listed name for NEO is NeoGenomics, Inc. Common Stock.

CEO

Douglas M. Van Oort

Employees

1,700

Headquarters

Fort Myers, Florida

Founded

1998

Market Cap

6.61B

Price-Earnings Ratio

—

Dividend Yield

—

Average Volume

846.73K

High Today

$55.97

Low Today

$51.03

Open Price

$53.00

Volume

995.54K

52 Week High

$61.57

52 Week Low

$20.47

NEO News

Benzinga11h

Recap: NeoGenomics Q4 Earnings

Shares of NeoGenomics (NASDAQ:NEO) were unchanged after the company reported Q4 results. Quarterly Results Earnings per share rose 40.00% over the past year t

Analyst Ratings

100%

of 11 ratings

Buy

100%

Hold

Sell

NEO Earnings

-$0.10

-$0.02

$0.06

$0.14

Q2 FY19

Q3 FY19

Q4 FY19

Q1 FY20

Q2 FY20

Q3 FY20

Q4 FY20

Estimated

$0.06 per share

Actual

$0.14 per share

Replay Earnings Call